GlassScriptPhysician profile
Aaron James Clay
NPI 1578941001
$13,806.99
in general payments reported to CMS, 2019-2025
32 companies · $3,288 in 2025
The $3,288 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $467 · 2021: $1,475 · 2022: $1,817 · 2023: $2,737 · 2024: $3,519 · 2025: $3,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,543.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,645.87 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,380.34 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,256.19 | 2019-2025 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $1,177.13 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $1,152.02 | 2022-2025 | Azstarys |
| Lundbeck LLC | $1,052.79 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $983.79 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $806.33 | 2019-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $688.59 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $599.34 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $485.29 | 2021-2022 | |
| Almatica Pharma LLC | $371.27 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $331.50 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $296.30 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $271.41 | 2020-2024 | Jornay Pm |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $220.17 | 2019-2025 | Dyanavel Xr |
| Biogen, INC. | $187.51 | 2024-2025 | Zurzuvae |
| Janssen Pharmaceuticals, INC | $169.74 | 2019-2023 | Spravato |
| Vertical Pharmaceuticals, LLC | $125.06 | 2023-2025 | Relexxii |
| Allergan, INC. | $95.05 | 2019-2020 | |
| Adlon Therapeutics L.P. | $74.65 | 2019-2021 | |
| Harmony Biosciences LLC | $71.42 | 2022-2024 | Wakix |
| Bausch Health US, LLC | $65.70 | 2024-2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $61.15 | 2025 | Jornay Pm |
| Eisai INC. | $52.87 | 2020-2021 | |
| Avion Pharmaceuticals | $40.95 | 2023 | Methylphenidate Hydrochloride |
| E.R. Squibb & Sons, L.L.C. | $40.32 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $27.71 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $27.38 | 2024 | Xelstrym, Secuado |
| Tempus Ai, INC | $19.27 | 2024 | Tempus Pixel |
| Abbott Laboratories | $16.18 | 2021 | |
| Neos Therapeutics, LP | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.